Shear Stress Activates ADAM10 Sheddase to Regulate Notch1 Via
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
ACE2/ADAM17/TMPRSS2 Interplay May Be the Main Risk Factor for COVID-19
REVIEW published: 07 October 2020 doi: 10.3389/fimmu.2020.576745 ACE2/ADAM17/TMPRSS2 Interplay May Be the Main Risk Factor for COVID-19 † † Donato Zipeto 1 , Julys da Fonseca Palmeira 2 , Gustavo A. Argañaraz 2 and Enrique R. Argañaraz 2* 1 Department of Neuroscience, Biomedicine and Movement Sciences, University of Verona, Verona, Italy, 2 Laboratory of Molecular Neurovirology, Faculty of Health Science, University of Bras´ılia, Brasilia, Brazil The Coronavirus Disease 2019 (COVID-19) has already caused hundreds of thousands of deaths worldwide in a few months. Cardiovascular disease, hypertension, diabetes and chronic lung disease have been identified as the main COVID-19 comorbidities. Moreover, Edited by: despite similar infection rates between men and women, the most severe course of the Yolande Richard, Institut National de la Sante´ et de la disease is higher in elderly and co-morbid male patients. Therefore, the occurrence of Recherche Me´ dicale (INSERM), specific comorbidities associated with renin–angiotensin system (RAS) imbalance France mediated by the interaction between angiotensin-converting enzyme 2 (ACE2) and Reviewed by: desintegrin and metalloproteinase domain 17 (ADAM17), along with specific genetic Andreas Ludwig, RWTH Aachen University, factors mainly associated with type II transmembrane serine protease (TMPRSS2) Germany expression, could be decisive for the clinical outcome of COVID-19. Indeed, the Elena Ciaglia, — University of Salerno, Italy exacerbated ADAM17 mediated ACE2, TNF-a, and IL-6R secretion emerges as a Rumi Ueha, possible underlying mechanism for the acute inflammatory immune response and the University of Tokyo, Japan activation of the coagulation cascade. Therefore, in this review, we focus on the main *Correspondence: pathophysiological aspects of ACE2, ADAM17, and TMPRSS2 host proteins in COVID- Enrique R. -
Advanced Glycation End Products Evoke Endothelial Cell Damage By
Ishibashi et al. Cardiovascular Diabetology 2013, 12:125 CARDIO http://www.cardiab.com/content/12/1/125 VASCULAR DIABETOLOGY ORIGINAL INVESTIGATION Open Access Advanced glycation end products evoke endothelial cell damage by stimulating soluble dipeptidyl peptidase-4 production and its interaction with mannose 6-phosphate/insulin- like growth factor II receptor Yuji Ishibashi1, Takanori Matsui1, Sayaka Maeda1, Yuichiro Higashimoto2 and Sho-ichi Yamagishi1* Abstract Background: Advanced glycation end products (AGEs) and receptor RAGE interaction play a role in diabetic vascular complications. Inhibition of dipeptidyl peptidase-4 (DPP-4) is a potential therapeutic target for type 2 diabetes. However, the role of DPP-4 in AGE-induced endothelial cell (EC) damage remains unclear. Methods: In this study, we investigated the effects of DPP-4 on reactive oxygen species (ROS) generation and RAGE gene expression in ECs. We further examined whether an inhibitor of DPP-4, linagliptin inhibited AGE-induced soluble DPP-4 production, ROS generation, RAGE, intercellular adhesion molecule-1 (ICAM-1) and plasminogen activator inhibitor-1 (PAI-1) gene expression in ECs. Results: DPP-4 dose-dependently increased ROS generation and RAGE gene expression in ECs, which were prevented by linagliptin. Mannose 6-phosphate (M6P) and antibodies (Ab) raised against M6P/insulin-like growth factor II receptor (M6P/IGF-IIR) completely blocked the ROS generation in DPP-4-exposed ECs, whereas surface plasmon resonance revealed that DPP-4 bound to M6P/IGF-IIR at the dissociation constant of 3.59 x 10-5 M. AGEs or hydrogen peroxide increased soluble DPP-4 production by ECs, which was prevented by N-acetylcysteine, RAGE-Ab or linagliptin. -
81969413.Pdf
View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector European Journal of Pharmacology 698 (2013) 74–86 Contents lists available at SciVerse ScienceDirect European Journal of Pharmacology journal homepage: www.elsevier.com/locate/ejphar Molecular and cellular pharmacology Dipeptidyl peptidase IV inhibition upregulates GLUT4 translocation and expression in heart and skeletal muscle of spontaneously hypertensive rats Gisele Giannocco a,b, Kelen C. Oliveira a,b, Renato O. Crajoinas c, Gabriela Venturini c, Thiago A. Salles c, Miriam H. Fonseca-Alaniz c, Rui M.B. Maciel b, Adriana C.C. Girardi c,n a Department of Morphology and Physiology, Faculdade de Medicina do ABC, Santo Andre´,Sao~ Paulo, SP, Brazil b Department of Medicine, Federal University of Sao~ Paulo, Sao~ Paulo, SP, Brazil c University of Sao~ Paulo Medical School, Heart Institute, Laboratory of Genetics and Molecular Cardiology, Avenida Dr. Ene´as de Carvalho Aguiar 44, 101 andar, Bloco II, 05403-900 Sao Paulo, Brazil article info abstract Article history: The purpose of the current study was to test the hypothesis that the dipeptidyl peptidase IV (DPPIV) Received 26 January 2012 inhibitor sitagliptin, which exerts anti-hyperglycemic and anti-hypertensive effects, upregulates GLUT4 Received in revised form translocation, protein levels, and/or mRNA expression in heart and skeletal muscle of spontaneously 19 September 2012 hypertensive rats (SHRs). Ten days of treatment with sitagliptin (40 mg/kg twice daily) decreased Accepted 21 September 2012 plasma DPPIV activity in both young (Y, 5-week-old) and adult (A, 20-week-old) SHRs to similar Available online 7 October 2012 extents (85%). -
3 Cleavage Products of Notch 2/Site and Myelopoiesis by Dysregulating
ADAM10 Overexpression Shifts Lympho- and Myelopoiesis by Dysregulating Site 2/Site 3 Cleavage Products of Notch This information is current as David R. Gibb, Sheinei J. Saleem, Dae-Joong Kang, Mark of October 4, 2021. A. Subler and Daniel H. Conrad J Immunol 2011; 186:4244-4252; Prepublished online 2 March 2011; doi: 10.4049/jimmunol.1003318 http://www.jimmunol.org/content/186/7/4244 Downloaded from Supplementary http://www.jimmunol.org/content/suppl/2011/03/02/jimmunol.100331 Material 8.DC1 http://www.jimmunol.org/ References This article cites 45 articles, 16 of which you can access for free at: http://www.jimmunol.org/content/186/7/4244.full#ref-list-1 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists by guest on October 4, 2021 • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2011 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology ADAM10 Overexpression Shifts Lympho- and Myelopoiesis by Dysregulating Site 2/Site 3 Cleavage Products of Notch David R. -
Structural Basis for the Sheddase Function of Human Meprin Β Metalloproteinase at the Plasma Membrane
Structural basis for the sheddase function of human meprin β metalloproteinase at the plasma membrane Joan L. Arolasa, Claudia Broderb, Tamara Jeffersonb, Tibisay Guevaraa, Erwin E. Sterchic, Wolfram Boded, Walter Stöckere, Christoph Becker-Paulyb, and F. Xavier Gomis-Rütha,1 aProteolysis Laboratory, Department of Structural Biology, Molecular Biology Institute of Barcelona, Consejo Superior de Investigaciones Cientificas, Barcelona Science Park, E-08028 Barcelona, Spain; bInstitute of Biochemistry, Unit for Degradomics of the Protease Web, University of Kiel, D-24118 Kiel, Germany; cInstitute of Biochemistry and Molecular Medicine, University of Berne, CH-3012 Berne, Switzerland; dArbeitsgruppe Proteinaseforschung, Max-Planck-Institute für Biochemie, D-82152 Planegg-Martinsried, Germany; and eInstitute of Zoology, Cell and Matrix Biology, Johannes Gutenberg-University, D-55128 Mainz, Germany Edited by Brian W. Matthews, University of Oregon, Eugene, OR, and approved August 22, 2012 (received for review June 29, 2012) Ectodomain shedding at the cell surface is a major mechanism to proteolysis” step within the membrane (1). This is the case for the regulate the extracellular and circulatory concentration or the processing of Notch ligand Delta1 and of APP, both carried out by activities of signaling proteins at the plasma membrane. Human γ-secretase after action of an α/β-secretase (11), and for signal- meprin β is a 145-kDa disulfide-linked homodimeric multidomain peptide peptidase, which removes remnants of the secretory pro- type-I membrane metallopeptidase that sheds membrane-bound tein translocation from the endoplasmic membrane (13). cytokines and growth factors, thereby contributing to inflammatory Recently, human meprin β (Mβ) was found to specifically pro- diseases, angiogenesis, and tumor progression. -
ADAM10 Site-Dependent Biology: Keeping Control of a Pervasive Protease
International Journal of Molecular Sciences Review ADAM10 Site-Dependent Biology: Keeping Control of a Pervasive Protease Francesca Tosetti 1,* , Massimo Alessio 2, Alessandro Poggi 1,† and Maria Raffaella Zocchi 3,† 1 Molecular Oncology and Angiogenesis Unit, IRCCS Ospedale Policlinico S. Martino Largo R. Benzi 10, 16132 Genoa, Italy; [email protected] 2 Proteome Biochemistry, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy; [email protected] 3 Division of Immunology, Transplants and Infectious Diseases, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy; [email protected] * Correspondence: [email protected] † These authors contributed equally to this work as last author. Abstract: Enzymes, once considered static molecular machines acting in defined spatial patterns and sites of action, move to different intra- and extracellular locations, changing their function. This topological regulation revealed a close cross-talk between proteases and signaling events involving post-translational modifications, membrane tyrosine kinase receptors and G-protein coupled recep- tors, motor proteins shuttling cargos in intracellular vesicles, and small-molecule messengers. Here, we highlight recent advances in our knowledge of regulation and function of A Disintegrin And Metalloproteinase (ADAM) endopeptidases at specific subcellular sites, or in multimolecular com- plexes, with a special focus on ADAM10, and tumor necrosis factor-α convertase (TACE/ADAM17), since these two enzymes belong to the same family, share selected substrates and bioactivity. We will discuss some examples of ADAM10 activity modulated by changing partners and subcellular compartmentalization, with the underlying hypothesis that restraining protease activity by spatial Citation: Tosetti, F.; Alessio, M.; segregation is a complex and powerful regulatory tool. -
Cell-Autonomous FLT3L Shedding Via ADAM10 Mediates Conventional Dendritic Cell Development in Mouse Spleen
Cell-autonomous FLT3L shedding via ADAM10 mediates conventional dendritic cell development in mouse spleen Kohei Fujitaa,b,1, Svetoslav Chakarovc,1, Tetsuro Kobayashid, Keiko Sakamotod, Benjamin Voisind, Kaibo Duanc, Taneaki Nakagawaa, Keisuke Horiuchie, Masayuki Amagaib, Florent Ginhouxc, and Keisuke Nagaod,2 aDepartment of Dentistry and Oral Surgery, Keio University School of Medicine, Tokyo 160-8582, Japan; bDepartment of Dermatology, Keio University School of Medicine, Tokyo 160-8582, Japan; cSingapore Immunology Network, Agency for Science, Technology and Research, Biopolis, 138648 Singapore; dDermatology Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD 20892; and eDepartment of Orthopedic Surgery, National Defense Medical College, Tokorozawa 359-8513, Japan Edited by Kenneth M. Murphy, Washington University School of Medicine, St. Louis, MO, and approved June 10, 2019 (received for review November 4, 2018) Conventional dendritic cells (cDCs) derive from bone marrow (BM) intocDC1sorcDC2stakesplaceintheBM(3),andthese precursors that undergo cascades of developmental programs to pre-cDC1s and pre-cDC2s ultimately differentiate into cDC1s terminally differentiate in peripheral tissues. Pre-cDC1s and pre- and cDC2s after migrating to nonlymphoid and lymphoid tissues. + + cDC2s commit in the BM to each differentiate into CD8α /CD103 cDCs are short-lived, and their homeostatic maintenance relies + cDC1s and CD11b cDC2s, respectively. Although both cDCs rely on on constant replenishment from the BM precursors (5). The cy- the cytokine FLT3L during development, mechanisms that ensure tokine Fms-related tyrosine kinase 3 ligand (FLT3L) (12), by cDC accessibility to FLT3L have yet to be elucidated. Here, we gen- signaling through its receptor FLT3 expressed on DC precursors, erated mice that lacked a disintegrin and metalloproteinase (ADAM) is essential during the development of DCs (7, 13). -
Effects of Glycosylation on the Enzymatic Activity and Mechanisms of Proteases
International Journal of Molecular Sciences Review Effects of Glycosylation on the Enzymatic Activity and Mechanisms of Proteases Peter Goettig Structural Biology Group, Faculty of Molecular Biology, University of Salzburg, Billrothstrasse 11, 5020 Salzburg, Austria; [email protected]; Tel.: +43-662-8044-7283; Fax: +43-662-8044-7209 Academic Editor: Cheorl-Ho Kim Received: 30 July 2016; Accepted: 10 November 2016; Published: 25 November 2016 Abstract: Posttranslational modifications are an important feature of most proteases in higher organisms, such as the conversion of inactive zymogens into active proteases. To date, little information is available on the role of glycosylation and functional implications for secreted proteases. Besides a stabilizing effect and protection against proteolysis, several proteases show a significant influence of glycosylation on the catalytic activity. Glycans can alter the substrate recognition, the specificity and binding affinity, as well as the turnover rates. However, there is currently no known general pattern, since glycosylation can have both stimulating and inhibiting effects on activity. Thus, a comparative analysis of individual cases with sufficient enzyme kinetic and structural data is a first approach to describe mechanistic principles that govern the effects of glycosylation on the function of proteases. The understanding of glycan functions becomes highly significant in proteomic and glycomic studies, which demonstrated that cancer-associated proteases, such as kallikrein-related peptidase 3, exhibit strongly altered glycosylation patterns in pathological cases. Such findings can contribute to a variety of future biomedical applications. Keywords: secreted protease; sequon; N-glycosylation; O-glycosylation; core glycan; enzyme kinetics; substrate recognition; flexible loops; Michaelis constant; turnover number 1. -
Tanibirumab (CUI C3490677) Add to Cart
5/17/2018 NCI Metathesaurus Contains Exact Match Begins With Name Code Property Relationship Source ALL Advanced Search NCIm Version: 201706 Version 2.8 (using LexEVS 6.5) Home | NCIt Hierarchy | Sources | Help Suggest changes to this concept Tanibirumab (CUI C3490677) Add to Cart Table of Contents Terms & Properties Synonym Details Relationships By Source Terms & Properties Concept Unique Identifier (CUI): C3490677 NCI Thesaurus Code: C102877 (see NCI Thesaurus info) Semantic Type: Immunologic Factor Semantic Type: Amino Acid, Peptide, or Protein Semantic Type: Pharmacologic Substance NCIt Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells, while VEGF is overexpressed in many tumors and is correlated to tumor progression. PDQ Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor -
HCC and Cancer Mutated Genes Summarized in the Literature Gene Symbol Gene Name References*
HCC and cancer mutated genes summarized in the literature Gene symbol Gene name References* A2M Alpha-2-macroglobulin (4) ABL1 c-abl oncogene 1, receptor tyrosine kinase (4,5,22) ACBD7 Acyl-Coenzyme A binding domain containing 7 (23) ACTL6A Actin-like 6A (4,5) ACTL6B Actin-like 6B (4) ACVR1B Activin A receptor, type IB (21,22) ACVR2A Activin A receptor, type IIA (4,21) ADAM10 ADAM metallopeptidase domain 10 (5) ADAMTS9 ADAM metallopeptidase with thrombospondin type 1 motif, 9 (4) ADCY2 Adenylate cyclase 2 (brain) (26) AJUBA Ajuba LIM protein (21) AKAP9 A kinase (PRKA) anchor protein (yotiao) 9 (4) Akt AKT serine/threonine kinase (28) AKT1 v-akt murine thymoma viral oncogene homolog 1 (5,21,22) AKT2 v-akt murine thymoma viral oncogene homolog 2 (4) ALB Albumin (4) ALK Anaplastic lymphoma receptor tyrosine kinase (22) AMPH Amphiphysin (24) ANK3 Ankyrin 3, node of Ranvier (ankyrin G) (4) ANKRD12 Ankyrin repeat domain 12 (4) ANO1 Anoctamin 1, calcium activated chloride channel (4) APC Adenomatous polyposis coli (4,5,21,22,25,28) APOB Apolipoprotein B [including Ag(x) antigen] (4) AR Androgen receptor (5,21-23) ARAP1 ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 1 (4) ARHGAP35 Rho GTPase activating protein 35 (21) ARID1A AT rich interactive domain 1A (SWI-like) (4,5,21,22,24,25,27,28) ARID1B AT rich interactive domain 1B (SWI1-like) (4,5,22) ARID2 AT rich interactive domain 2 (ARID, RFX-like) (4,5,22,24,25,27,28) ARID4A AT rich interactive domain 4A (RBP1-like) (28) ARID5B AT rich interactive domain 5B (MRF1-like) (21) ASPM Asp (abnormal -
Loss of Protease Activity of ADAM15 Abolishes Protective Effects on Plaque Progression in Atherosclerosis
382 Letters to the Editor Loss of protease activity of ADAM15 abolishes protective effects on plaque progression in atherosclerosis Andreas Bültmann, Zhongmin Li, Silvia Wagner, Meinrad Gawaz, Martin Ungerer, Harald Langer, Andreas E. May ⁎⁎, Götz Münch ⁎ Corimmun, Fraunhofer Str. 17, D-82152 Martinsried, Germany Medizinische Klinik III, Eberhard-Karls Universität Tübingen, D-72076 Tübingen, Germany article info For the induction of atherosclerosis, rabbits were fed with Western Article history: type high cholesterol (0.25%) diet for 8 weeks and vascular gene Received 8 August 2011 transfer to the carotid artery was performed as previously described Accepted 13 August 2011 [7]. Available online 9 September 2011 Animals were sacrificed 4 weeks after the adenovirus delivery. Keywords: The left common carotid arteries, aorta and iliac arteries were Atherosclerosis macroscopically prepared for “en face” evaluation of plaque ADAM15 extension and stained with Sudan III. Serial 6-μm-thick cryosections Sheddase were cut and histological assessment of atherosclerosis after Metalloproteinase hematoxylin eosin (HE) and van Gieson (VG)-elastica staining and GFP expression were performed. Immunohistochemical analysis, with anti rabbit RAM 11 antibody (DAKO, Hamburg, Germany) was The A Disintegrin And Metallporteinases (ADAMs) contain a used for macrophages as previously described [12]. metalloprotease-like and a disintegrin-like domain. Currently 40 After vascular gene transfer into the carotid artery, GFP expression different types of ADAM proteins have been identified. ADAM15 is could be detected with AdGFP and also with Ad-ADAM15 and Ad- found in the myocardium [1,2], endothelial cells and in vascular ADAM15 prot neg, which both co-expressed GFP (Fig. 1). Relative atherosclerotic lesions [3]. -
Ectodomain Shedding May Play a Pivotal Role in Disease Severity in COVID-19
https://www.scientificarchives.com/journal/journal-of-cellular-signaling Journal of Cellular Signaling Commentary Ectodomain Shedding May Play a Pivotal Role in Disease Severity in COVID-19 Rui Yamaguchi, Yasuo Yamaguchi* Graduate School of Medical Science, Kumamoto Health Science University, Kitaku Izumi-machi 325 Kumamoto 861-5598, Japan *Correspondence should be addressed to Yasuo Yamaguchi; [email protected] Received date: April 16, 2021, Accepted date: May 21, 2021 Copyright: © 2021 Yamaguchi R, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Ectodomain shedding mediated by a disintegrin and (ROS) [2]. ADAM10/7 was found to mediate ectodomain metalloprotease 10/17 (ADAM10/17) modulates the shedding to modulate immune responses [3] and to function of immune effector cells and may be involved in be activated by ROS [4]. These findings suggest that the novel coronavirus disease COVID-19. Toll-like receptor SARS-CoV-2 contributes to and induces ectodomain 7/8 (TLR7/8) recognizes single-strand RNA from viruses shedding, which may be associated with disease severity. such as severe acute respiratory syndrome coronavirus In patients with COVID-19, studies found a higher blood 2 (SARS-CoV-2, the virus that causes COVID-19) during concentration of the chemokine fractalkine [5]. Cell the innate immune response [1], and TLR7/8 agonist membrane-bound angiotensin-converting enzyme 2 activates nicotinamide adenine dinucleotide phosphate (ACE2) has been identified as a binding site and entry (NADPH) oxidase to generate reactive oxygen species receptor for the spike protein of SARS-CoV-2.